Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia
This study is currently recruiting patients.
Sponsored by: | FDA Office of Orphan Products Development University of North Carolina
|
---|---|
Information provided by: | FDA Office of Orphan Products Development |
Purpose
OBJECTIVES: I. Compare the efficacy of hydroxyurea with or without clotrimazole in terms of limiting the severity of anemia and the rate of hemolysis in patients with sickle cell anemia.
Condition | Treatment or Intervention | Phase |
---|---|---|
Sickle Cell Anemia |
Drug: clotrimazole Drug: hydroxyurea |
Phase I Phase II |
MedlinePlus related topics: Sickle Cell Anemia
Genetics Home Reference related topics: sickle cell anemia
Study Type: Interventional
Study Design: Treatment, Randomized
Expected Total Enrollment: 20
Study start: October 1999
PROTOCOL OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms. Arm I: Patients receive oral hydroxyurea and oral clotrimazole daily for 12 months. Arm II: Patients receive oral hydroxyurea daily for 12 months. Patients are followed at 6 weeks.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Diagnosis of sickle cell anemia confirmed by hemoglobin electrophoresis
Received hydroxyurea for at least 6 months On a stable dose for at least 3 months Tolerating dose of at least 5 mg/kg/day
--Prior/Concurrent Therapy--
Chemotherapy:
Other: No concurrent drug that may interact with or influence the metabolism of hydroxyurea or clotrimazole
--Patient Characteristics--
Hematopoietic: WBC at least 4000/mm3 Platelet count at least 150,000/mm3 Hemoglobin less than 11 g/dL
Hepatic: AST/ALT no greater than 100 units/L
Renal: Creatinine no greater than 1.5 mg/dL
Other:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |